PDF of Trial CTRI Website URL -

Similar documents
PDF of Trial CTRI Website URL -

MULTICENTER CLINICAL AND INSTRUMENTAL STUDY FOR THE EVALUATION OF EFFICACY AND TOLERANCE OF AN INTRADERMAL INJECTABLE PRODUCT AS A FILLER AND A

Antiaging Treatments. Natalia Jiménez. Hospital Universitario Ramón y Cajal Grupo de Dermatología Pedro Jaén

The secondary objective was to evaluate the cosmetic properties and its efficacy after 28 days.

To acclimate skin to AHAs prior to a peel Anti-aging, exfoliation, builds collagen. Gentle cleanser to remove sebum, skin debris and makeup.

PDF of Trial CTRI Website URL -

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

NEWS RELEASE. CONTACTS: Investors: Lisa DeFrancesco (862) Media: Mark Marmur (862) Ember Garrett (714)

MANNATECH SKIN CARE PRODUCT SAFETY AND EFFICACY TESTING

Tolerance of a Low-Level Blue and Red Light Therapy Acne Mask in Acne Patients with Sensitive Skin

CLINICAL EVALUATION OF REVIVOGEN TOPICAL FORMULA FOR TREATMENT OF MEN AND WOMEN WITH ANDROGENETIC ALOPECIA. A PILOT STUDY

EpiCeram Topical therapeutic Skin Barrier Emulsion

Management of acne requires proper application

CHEMICAL SKIN PEELING

CUPRON PILLOWCASE STUDY. Summer 2009

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

designed to stimulate collagen

MARK D. EPSTEIN, M.D. F.A.C.S. Hyaluronic Acid (HA) INJECTION - INFORMATION FOR PATIENTS

TEOSYAL PEN: Personal experience after 12 months on 285 consecutive patients

Client Intake Form. Name: Date: Address: City: ST: Zip: Phone:

*Resilient Hyaluronic Acid

Results Clinical Photography

A novel daily moisturizing cream for effective management of mild to moderate Atopic Dermatitis in infants and children

Personal Care. Industrial & Consumer Specialties. A unique solution for complete skin repair. Vitipure TM

The CARI Guidelines Caring for Australians with Renal Impairment. 12. Prophylaxis for exit site/tunnel infections using mupirocin

Lisa Chipps, MD, MS, FAAD Assistant Clinical Professor David Geffen School of Medicine at UCLA

Pearl Fusion Technique

GSK Clinical Study Register

PRESS MATERIAL. Contents: Appendix: Backgrounder Q-Med 2 Backgrounder RESTYLANE 3 Questions and answers 5 Recommended reading 7

Five-Year Safety and Efficacy of a Novel Polymethylmethacrylate Aesthetic Soft Tissue Filler for the Correction of...

RISKS AND HEALTH EFFECTS FROM TATTOOS, BODY PIERCING AND RELATED PRACTICES

EVERYONE WILL NOTICE. No One Will Know.

Massey Medical. Medical History (Dermal Filler) MEDICAL INFORMATION: I am interested in the following services: Juvederm: Botox:

Own Your Beauty. with the Belotero range. Enjoy natural results with a filler tailored to your needs.

Skin Health: Collagen Peptides for a Young and Beautiful Look

CLEAR TOE INTAKE INFORMATION

BRAND HIGHLIGHTS. Growth has not come from PR but purely word of mouth CULT51 enjoys a 76% re-buy rate

Peri-Orbital Non-Invasive and Painless Skin Tightening-Safe and Highly Effective Use of Multisource Radio-Frequency Treatment Platform

Imbue Aesthetics & Wellness PATIENT REGISTRATION FORM

Maya Med Spa 6330 Broadway Blvd. Suite B, Garland, TX Name: Date of birth: Address: Pharmacy of your choice:

NEW CLIENT GENERAL INFORMATION FORM

Clinical Policy: Lindane Shampoo Reference Number: CP.PMN.09 Effective Date: Last Review Date: Line of Business: Oregon Health Plan

Complete Dermal Integration. Proven Duration.

Prospective Patient Application

Literature Scan: Topical Antiparasitics

Informed Consent for Light Energy Tattoo Removal

POLYTAR Plus Liquid PRODUCT INFORMATION. Polytar Plus Liquid medicated scalp cleanser, contains coal tar solution.

Vider Itzhak MD2, Harth Yoram MD2,, Elman Monica MD, Gottfried Varda PhD3, Shemer Avner MD4, Beit Harofim

HOW WOULD YOU DEFINE BEAUTY?

Rodan + Fields Dermatologists Skincare Changing skin and changing lives. The Perfect Partnership

Best Cosmeceutical Skincare Range UK 2013

Module 1. Introduction to Aesthetic Medicine: Nonsurgical

NIGHTTIME ANTIOXIDANT

Topical Steroid Therapy. Shireen Velangi Consultant Dermatology Queen Elizabeth Hospital Birmingham UK

Regulation of Sunscreens in Australia

Aesthetic Patient Form

Levan. A Natural Anti-Aging Humectant

Package leaflet: Information for the user. ZORAC 0.05% gel ZORAC 0.1% gel. Tazarotene

REF Rev. 4

New Filler Approvals Refyne, Defyne, Vollure, Revanesse. Karol A Gutowski, MD, FACS Hot Topics

Joel Schlessinger, MD, FAAD, FAACS; Jeffrey Kenkel, MD, FACS; and Philip Werschler, MD, FAAD. Cosmetic Medicine

HOW TO USE. and make the most out of your CTCL treatment

Informed Consent for Dermal Filler

Technological innovation for the treatment of hair loss*

COLORADO AESTHETIC CENTER

Type of Application (Check One) New Protocol Revised Protocol Project Duration Start Date: End Date:

Brilliant Bodywork. Name: Date: Address: City: State: Zip: Home Phone: Business Phone: Cell Phone: Date of Birth: address:

COURSE TOPICS WHO CAN PARTICIPATE?

J.C. van Montfort, MD, Van Montfort Laboratories BV, Brightlands Maastricht Health Campus, Maastricht

Dermal fillers have steadily grown in use over the. Juvéderm Injectable Gel: A Multicenter, Double-Blind, Randomized Study of Safety and Effectiveness

S Main St, Kaysville, UT 84037

Redermalization. Procedure guideline. «Workbook» ... The Formula of Anti-Age Synergy

Hyalurosmooth. by Beauty Creations. Natural fine line and wrinkle filler

New Patient Registration

ACCUTANE SKIN RASH HANDS

Effect of a new topical treatment on androgenetic and telogen hair loss in women

VTCT Level 2 NVQ Award in Providing Pedicure Services

SPINCONTROL GROUP & SPINCONTROL ASIA

HIS AND HER AGING CONCERNS. For both men and women, aging is inevitable. Both genders suffer

SPECIAL TOPIC. Virginia Clinical Research, Inc., Norfolk, VA b. Oregon Dermatology and Research Center, Portland, OR c

PRE-CONGRESS. Tuesday, November 7 th, 2017 HOSPITAL Registration PRE-CONGRESS WORKSHOP LIPOSUCTION AND LIPOTRANSFER LIVE 09.

while still performed, is not always the most desired procedure can be individualized to meet his or her specific needs.

Patient Information Leaflet. Dermal Filler

MICRONEEDLING DEVICE (SKIN ROLLER) ENHANCES SKIN S ABSORPTION OF PRODUCTS

Micro-fractional Laser Skin Rejuvenation : Enhanced Outcomes with Novel Multi-Modality and Multi-Wavelength Treatment Paradigms

Safety and Efficacy of a Novel Diffractive Lens Array Using a Picosecond 755 nm Alexandrite Laser for Treatment of Wrinkles

Client Information Sheet

JDDonline.com. Introduction. Methods Study Design Twenty-three patients enrolled in a 4-week, multicenter, investigator-blinded,

Q-switched Nd:YAG Carbon Laser Facial Further treatment possible using your Tattoo Removal Laser

Patient Information. M.I. Address: DOB: Sex: M F City: State: Zip: Social Security Number: / / Whom may we thank for referring you?

Evaluation of Cosmeceutical Ingredients: What the Label May Not Reveal Patrick Bitter, MD. Regulation of Topical Skin Care Products.

Patients should be given information about skin reactions and self-care strategies. A recent UK survey found that:

513 Maple Ave West, Vienna, VA

Hard as nails New study shows that supplementation with GELITA s VERISOL helps to restore nail strength in women affected by brittle nail syndrome

Last Name: First Name: Address: Apt: City: State:

LaraCare A200 Your Multi-Functional Larch Tree Active

Case Study for Ablative and Non-Ablative Facial Treatment with Lux2940 Groove and Lux1440 Handpieces

AREA OF BODY TATTOO IS SITUATED?

INJECTABLES. Botox Cosmetic Page 1 of 7. FAQ s

Hair Restoration Gel

Transcription:

Clinical Trial Details (PDF Generation Date :- Tue, 02 Oct 2018 21:40:33 GMT) CTRI Number Last Modified On 26/12/2012 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study Scientific Title of Study CTRI/2012/02/002465 [Registered on: 28/02/2012] - Trial Registered Prospectively No Interventional Ayurveda Randomized, Parallel Group, Placebo Controlled Trial Study to evaluate the effectiveness and tolerance of herbal anti wrinkle cream in facial wrinkles of Healthy Human Subjects A Phase II, double blind placebo controlled, monocentric study to evaluate the efficacy and tolerance of herbal anti wrinkle cream in facial wrinkles of Healthy Human Subjects Secondary IDs if Any Secondary ID Identifier Details of Principal Investigator or overall Trial Coordinator (multi-center study) Details Contact Person (Scientific Query) Designation Affiliation Details of Principal Investigator Principal Investigator MS Clinical Phone 080-40917253 Fax 080-41125934 Email Designation Affiliation MS CLINICAL RESEARCH PVT. LTD, Mezzanine Floor, Classic Court, 9/1 Richmond Road, Bangalore-560025, Karnataka Bangalore 560025 mukta.sachdev@mscr.in Details Contact Person (Scientific Query) Principal Investigator MS Clinical MS CLINICAL RESEARCH PVT. LTD, Mezzanine Floor, Classic Court, 9/1 Richmond Road, Bangalore-560025, Karnataka Details Contact Person (Public Query) 560025 Phone 080-40917253 Fax 080-41125934 Email Designation Affiliation mukta.sachdev@mscr.in Details Contact Person (Public Query) Principal Investigator MS Clinical MS CLINICAL RESEARCH PVT. LTD, Mezzanine Floor, Classic Court, 9/1 Richmond Road, Bangalore-560025, Karnataka 560025 page 1 / 7

Source of Monetary or Material Support Primary Sponsor Details of Secondary Sponsor Countries of Recruitment Sites of Study Details of Ethics Committee Regulatory Clearance Status from DCGI Health Condition / Problems Studied Intervention / Comparator Agent Inclusion Criteria Phone 080-40917253 Fax 080-41125934 Email > Type of Sponsor List of Countries of Principal Investigator mukta.sachdev@mscr.in Source of Monetary or Material Support Primary Sponsor Details THE HIMALAYA DRUG COMPANY Makali, Bangalore 562123, Karnataka, Pharmaceutical industry-n of Site Site Phone/Fax/Email MS Clinical Research Pvt Ltd Mezzanine Floor, Classic Court, 9/1 Richmond Road, Bangalore-560025, Karnataka Bangalore 080-40917253 080-41125934 mukta.sachdev@mscr.i n of Committee Approval Status Date of Approval Is Independent Ethics Committee? Independent Ethics Committe- Aditya, Ahmedabad, Dr. Mukta Sachdev Status Health Type Healthy Human Volunteers Approved 17/01/2012 Yes Date No Date Specified Condition Apparent mild to moderate crow s feet in unanimated face Type Details Intervention Herbal anti wrinkle cream apply the provided Investigational product required quantity (app.0.5 gms) to cover the whole face twice daily (12 weeks per subject) Comparator Agent Placebo apply the provided Investigational product required quantity(app.0.5 gms) to cover the whole face twice daily(12 weeks per subject) Age From Age To Gender Details 30.00 Year(s) 65.00 Year(s) Female Inclusion Criteria Female subjects in generally good health Subjects of skin types III, IV, and V. page 2 / 7

Exclusion Criteria Method of Generating Random Sequence Method of Concealment Blinding/Masking Details Other Participant and Investigator Blinded Subjects age group 30-65 years Subjects willing to give a written informed consent and come for a regular follow up. Subject willing to abide by and comply with the study protocol Subject has not participated in a similar investigation in the past four weeks. Subjects having visible fine lines and wrinkles in periorbital area (Crow s feet), nasolabial areas, forehead,and perioral regions of the face Subjects having mild to moderate nasolabial folds Subjects having apparent mild to moderate crow s feet in unanimated face Subjects who have not under gone any facial anti ageing procedures (e.g. Botulinum toxin, dermal filler injections, laser resurfacing) in the past 3 months. Subject should be willing to abstain from spa treatments/facials during the study period Exclusion Criteria A known history or present condition of allergic response to any cosmetic products. Subjects having severe photoaging. Subject having skin diseases (e.g. moderate to severe acne vulgaris face or nodulocystic acne, psoriasis, active atopic dermatitis, melasma, lichen planus pigmentosus/ Achy dermatosis, pigmented contact dermatitis or other cutaneous manifestations), which will interfere with the test readings. Subjects on oral medications (e.g. steroids, anti-oxidant) which will compromise the study. Systemic treatment which may modify the cutaneous state on the day of inclusion or in the previous 30 days, including retinoid therapy. Subjects not willing to discontinue other topical anti ageing, anti wrinkle facial products. Subjects who are pregnant, lactating or nursing. Hypersensitivity to any component of the tested products. History of intense sun exposure. Chronic illness which may influence the cutaneous state. Subject participating in any other cosmetic or therapeutic trial. Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness Primary Outcome Outcome Timepoints 1. Improvement by reduction in number and depth of facial wrinkles, finelines, nasolabial fold, crow s feet area in comparison to baseline. 2. Improvement by reduction in number and depth of facial wrinkles, finelines, nasolabial fold, crow s feet area in comparison to placebo Day 1, Day 28,Day 56 and Day 84 Secondary Outcome Outcome Timepoints Target Sample Size Total Sample Size=40 Sample Size from =40 page 3 / 7

Phase of Trial Phase 2 Date of First Enrollment () Date of First Enrollment (Global) Estimated Duration of Trial Recruitment Status of Trial (Global) Recruitment Status of Trial () Publication Details Brief Summary 01/03/2012 No Date Specified Years=0 Months=3 Days=0 Completed A Phase II, double blind placebo controlled, monocentric study to evaluate the efficacy an tolerance of herbal anti wrinkle cream in facial wrinkles of Healthy Human Subjects. a. Primary objectives To study product performance in reduction in number and depth of facial wrinkles, fine line nasolabial fold and crow s feet in comparison to baseline and placebo by followin parameters: Dermatologist s assessment Subject s self assessment Instrumental measurements- Visioscan and Visioline b. Secondary objective To study product performance in reduction of facial wrinkles in comparison t baseline and placebo by evaluating photographically apparent aging with Imaging system Image pro II Instrument measurement with corneometer to evaluate the moisturizatio effect in comparison to baseline and placebo Assessment for adverse events page 4 / 7

Double blind, placebo controlled, monocentric Total 34 + 6 subjects (to compensate drop outs if any) Dermatologist s visual assessment Dermatologists assessments for adverse events Instrumental measurements- Visioscan, visioline & corneometer Assessment with Imaging system- Image pro II Subject s self assessment. Herbal anti wrinkle cream Placebo Healthy female subjects aged between 30-65 years of skin type III, IV and V with faci wrinkles. Medical history, general physical examination, dermatological assessment Female subjects in generally good health page 5 / 7

Subjects of skin types III, IV, and V. Subjects age group 30-65 years Subjects willing to give a written informed consent and come for a regular follo up. Subject willing to abide by and comply with the study protocol Subject has not participated in a similar investigation in the past four weeks. Subjects having visible fine lines and wrinkles in periorbital area (Crow s feet), nasolabial areas, forehead,and perioral regions of the face Subjects having mild to moderate nasolabial folds Subjects having apparent mild to moderate crow s feet in unanimated face Subjects who have not under gone any facial anti ageing procedures (e.g. Botulinum toxin, dermal filler injections, laser resurfacing) in the past 3 months. Subject should be willing to abstain from spa treatments/facials during the study period A known history or present condition of allergic response to any cosmet products. Subjects having severe photoaging. Subject having skin diseases (e.g. moderate to severe acne vulgaris face o nodulocystic acne, psoriasis, active atopic dermatitis, melasma, lichen planus pigmentosu Achy dermatosis, pigmented contact dermatitis or other cutaneous manifestations), which wi interfere with the test readings. Subjects on oral medications (e.g. steroids, anti-oxidant) which will compromis the study. Systemic treatment which may modify the cutaneous state on the day of inclusio or in the previous 30 days, including retinoid therapy. Subjects not willing to discontinue other topical anti ageing, anti wrinkle faci products. Subjects who are pregnant, lactating or nursing. page 6 / 7

Powered by TCPDF (www.tcpdf.org) PDF of Trial Hypersensitivity to any component of the tested products. History of intense sun exposure. Chronic illness which may influence the cutaneous state. Subject participating in any other cosmetic or therapeutic trial. Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness. 84 days (12 weeks) for each volunteer page 7 / 7